Ensuring a steady, uninterrupted supply of Technetium 99m for our customers and the patients they serve is our top priority. Mallinckrodt is continuously making investments to increase worldwide stability of Mo-99 by constantly evaluating all potential long-term global supply opportunities and solutions.
Mallinckrodt’s Mo-99 LEU Conversion Efforts:
Conversion from high enriched uranium or HEU to low enriched uranium or LEU for Mo-99 production:
Demand for reliable, large-scale U.S. manufacture of Mo-99 using low-enriched uranium (LEU) technology.
Mallinckrodt’s Continued Investment in Manufacturing:
Investments are being made to our U.S. manufacturing facilities and products to improve quality and reliability.
Mallinckrodt, the “M” brand mark, and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2015 Mallinckrodt.
Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.